Lactobacillus reuteri in children with functional abdominal pain (FAP)
Article first published online: 8 JUL 2010
© 2010 The Authors. Journal compilation © 2010 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
Journal of Paediatrics and Child Health
Volume 50, Issue 10, pages E68–E71, October 2014
How to Cite
Romano, C., Ferrau', V., Cavataio, F., Iacono, G., Spina, M., Lionetti, E., Comisi, F., Famiani, A. and Comito, D. (2014), Lactobacillus reuteri in children with functional abdominal pain (FAP). Journal of Paediatrics and Child Health, 50: E68–E71. doi: 10.1111/j.1440-1754.2010.01797.x
- Issue published online: 6 OCT 2014
- Article first published online: 8 JUL 2010
- Accepted for publication 1 February 2010.
- functional abdominal pain;
- functional gastrointestinal disorders (FGID);
Aim: Functional abdominal pain (FAP) is a frequent condition affecting 10–20% of children and can be considered within the classification of functional gastrointestinal disorders (FGID). The objective of this study was to determine the effect of daily supplementation with the probiotic Lactobacillus reuteri DSM 17938 in children with FAP.
Methods: The children (aged 6–16 years) were screened for FAP as defined in the Rome III criteria and 60 patients were recruited in this double-blind, randomised, placebo-controlled trial. The children were randomly allocated to receive either L. reuteri (2 × 108 CFU/day) or identical placebo for 4 weeks followed by a 4-week follow-up period without supplementation. Frequency and intensity of pain was self-recorded by the subjects.
Results: The L. reuteri-supplemented children had significantly lower pain intensity compared with the placebo controls.
Conclusions: Supplementation with L. reuteri reduced perceived abdominal pain intensity, which may encourage clinicians to use this probiotic in children with FAP.